The estimated Net Worth of Eric Sievers is at least $1.05 Milion dollars as of 30 November 2021. Dr Sievers owns over 1,124 units of BioAtla stock worth over $163,796 and over the last 4 years he sold BCAB stock worth over $329,111. In addition, he makes $552,616 as Chief Medical Officer at BioAtla.
Dr has made over 5 trades of the BioAtla stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,124 units of BCAB stock worth $25,031 on 30 November 2021.
The largest trade he's ever made was selling 6,883 units of BioAtla stock on 26 August 2021 worth over $272,498. On average, Dr trades about 218 units every 2 days since 2020. As of 30 November 2021 he still owns at least 91,506 units of BioAtla stock.
You can see the complete history of Dr Sievers stock trades at the bottom of the page.
Dr. Eric L. Sievers M.D. is the Chief Medical Officer at BioAtla.
As the Chief Medical Officer of BioAtla, the total compensation of Dr D at BioAtla is $552,616. There are 2 executives at BioAtla getting paid more, with Dr. Jay M. Short having the highest compensation of $1,057,577.
Dr D is 57, he's been the Chief Medical Officer of BioAtla since . There are 3 older and 2 younger executives at BioAtla. The oldest executive at BioAtla, Inc. is Richard A. Waldron, 67, who is the Chief Financial Officer.
Eric's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B... oraz Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BioAtla executives and other stock owners filed with the SEC include: